Results 61 to 70 of about 215,033 (246)
It's Not Easy Being Gray: The New Rules of Retirement [PDF]
, 2009 Examines changes in the factors involved in retirement, including the labor market for older workers, demands and limitations of working longer, the effect of rising healthcare costs, and adequacy of retirement income.
core
Coverage generosity of novel anti‐rheumatic drugs in Medicare Advantage and stand‐alone Part D plans
Arthritis &Rheumatology, Accepted Article.Objective To examine coverage of self‐administered disease‐modifying anti‐rheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022‐2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T‐cell co‐stimulatory modulator, Interleukin‐6 ...
Youngmin Kwon +2 more
wiley +1 more source
Medigap Reforms: Potential Effects of Benefit Restrictions on Medicare Spending and Beneficiary Costs [PDF]
, 2011 Analyzes how three options for reforming Medicare supplemental insurance policies that help cover cost-sharing requirements would affect Medicare spending and beneficiary spending by income level, health status, and inpatient hospital ...
Mark Merlis
core
Essential work, invisible workers: The role of digital curation in COVID‐19 Open Science
Journal of the Association for Information Science and Technology, Volume 76, Issue 4, Page 703-717, April 2025.Abstract In this paper, we examine the role digital curation practices and practitioners played in facilitating open science (OS) initiatives amid the COVID‐19 pandemic. In Summer 2023, we conducted a content analysis of available information regarding 50 OS initiatives that emerged—or substantially shifted their focus—between 2020 and 2022 to address ...
Irene V. Pasquetto +2 more
wiley +1 more source
The Employer-based Health-Insurance System (EBI) Is At Risk: What We Must Do About It [PDF]
, 2007 This report presents the first two parts of CED's research and covers the scope of the crisis in health care and the options for fixing the system. A third part offering CED's recommendations, Quality, Affordable Health Care for All: Moving Beyond the ...
core
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani +4 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley +1 more source
An In-Depth Examination of Formularies and Other Features of Medicare Drug Plans [PDF]
, 2006 Provides a detailed assessment of the formularies, drug costs, and utilization management tools offered by the fourteen nationwide organizations that account for most of the stand-alone prescription drug ...
Elizabeth Hargrave +3 more
core
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study. [PDF]
, 2017 Background: Published evidence indicates that individual use of metformin and statin is associated with reduced cancer mortality. However, their differential and joint effects on pancreatic cancer survival are inconclusive.Methods: We identified a large ...
Demissie, Kitaw +9 more
core +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer +4 more
wiley +1 more source